FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379285737> ?p ?o ?g. }

• W4379285737 endingPage "1095" @default.
• W4379285737 startingPage "1095" @default.
• W4379285737 abstract "1095 Background: Metastatic breast cancer is incurable, and novel treatment (tx) strategies are needed. Single agent immune checkpoint inhibitor (ICI) tx has limited efficacy; combination approaches may yield better results. Multiple mechanisms of glucocorticoid-induced immunosuppression have been proposed, including the suppression of the cytotoxic Th1 cytokine response via glucocorticoid receptor (GR) activation. We hypothesize that pretreatment with a GR antagonist shifts the cytotoxic immune response toward Th1, thus enhancing response to ICIs. We present the safety and efficacy of the combination of pembrolizumab and mifepristone in advanced HER2-negative breast cancer. Methods: This (NCT03225547) was a phase II non-randomized study of pembrolizumab and mifepristone in patients (pts) with advanced HER2-negative breast cancer. Pts with prior ICI tx were excluded. Pts received mifepristone 300mg daily and pembrolizumab 200mg every 3 weeks; mifepristone was started 7 days prior to pembrolizumab. The primary endpoint was objective response rate (ORR). Secondary endpoints included progression-free survival (PFS), overall survival (OS), disease control rate (DCR), and safety and tolerability. Results: 18 patients were enrolled from March 2018 – November 2020; 10 patients with TNBC (cohort 1) and 8 patients with HR+ BC (cohort 2). Mean age was 53 yrs (range 33-74) and 33% of patients were self-reported Black. In cohort 1, 50% of patients were tx naive in this advanced setting, and 90% of patients had < 2 prior lines of tx. In cohort 2, 25% of patients had not received prior chemo in the metastatic setting. The overall ORR was 6%. One pt with TNBC had a complete response (CR). She received 36 cycles of tx; tx was discontinued due to mucositis and rash, and she remains in CR at >48 mos from start of tx. No patients in cohort 2 had a partial or complete response. The most common treatment-related adverse events were rash (61%), thyroid abnormality (17%), and pruritis (17%). 45% of patients experienced a grade 3 or 4 adverse event; all except one (hypokalemia) were due to rash. Rash was described as maculopapular dermatitis. The DCR at 18 weeks was 33.3% in the overall population; it was 44.4% in cohort 1 and 16.7% in cohort 2. Overall median PFS was 1.9 months [95% CI 1.8 – 3.6]. Overall median OS was 12.9 months [95% CI 5.8 – 23.0]. Conclusions: While this regimen demonstrated efficacy in a small subset of patients, including one pt with long-term CR, given the non-randomized design, we cannot determine if mifepristone enhanced the efficacy of ICI. In addition, a higher than anticipated rate of skin toxicity, possibly related to mifepristone enhancing the activity of ICI, was observed in the study, leading to early closure. While the benefit/risk analysis of this combination does not support further evaluation, additional investigation of alternative chemotherapy-free, immunomodulatory strategies is warranted. Clinical trial information: NCT03225547 ." @default.
• W4379285737 created "2023-06-05" @default.
• W4379285737 creator A5005007467 @default.
• W4379285737 creator A5006194387 @default.
• W4379285737 creator A5008089396 @default.
• W4379285737 creator A5031652616 @default.
• W4379285737 creator A5038171309 @default.
• W4379285737 creator A5046031005 @default.
• W4379285737 creator A5056264181 @default.
• W4379285737 creator A5077423550 @default.
• W4379285737 creator A5085083246 @default.
• W4379285737 creator A5091316016 @default.
• W4379285737 date "2023-06-01" @default.
• W4379285737 modified "2023-10-16" @default.
• W4379285737 title "Phase II study of pembrolizumab plus mifepristone in patients with advanced HER2-negative breast cancer." @default.
• W4379285737 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.1095" @default.
• W4379285737 hasPublicationYear "2023" @default.
• W4379285737 type Work @default.
• W4379285737 citedByCount "0" @default.
• W4379285737 crossrefType "journal-article" @default.
• W4379285737 hasAuthorship W4379285737A5005007467 @default.
• W4379285737 hasAuthorship W4379285737A5006194387 @default.
• W4379285737 hasAuthorship W4379285737A5008089396 @default.
• W4379285737 hasAuthorship W4379285737A5031652616 @default.
• W4379285737 hasAuthorship W4379285737A5038171309 @default.
• W4379285737 hasAuthorship W4379285737A5046031005 @default.
• W4379285737 hasAuthorship W4379285737A5056264181 @default.
• W4379285737 hasAuthorship W4379285737A5077423550 @default.
• W4379285737 hasAuthorship W4379285737A5085083246 @default.
• W4379285737 hasAuthorship W4379285737A5091316016 @default.
• W4379285737 hasConcept C121608353 @default.
• W4379285737 hasConcept C126322002 @default.
• W4379285737 hasConcept C143998085 @default.
• W4379285737 hasConcept C197934379 @default.
• W4379285737 hasConcept C203092338 @default.
• W4379285737 hasConcept C2775930923 @default.
• W4379285737 hasConcept C2777701055 @default.
• W4379285737 hasConcept C2778375690 @default.
• W4379285737 hasConcept C2780057760 @default.
• W4379285737 hasConcept C530470458 @default.
• W4379285737 hasConcept C535046627 @default.
• W4379285737 hasConcept C71924100 @default.
• W4379285737 hasConcept C72563966 @default.
• W4379285737 hasConceptScore W4379285737C121608353 @default.
• W4379285737 hasConceptScore W4379285737C126322002 @default.
• W4379285737 hasConceptScore W4379285737C143998085 @default.
• W4379285737 hasConceptScore W4379285737C197934379 @default.
• W4379285737 hasConceptScore W4379285737C203092338 @default.
• W4379285737 hasConceptScore W4379285737C2775930923 @default.
• W4379285737 hasConceptScore W4379285737C2777701055 @default.
• W4379285737 hasConceptScore W4379285737C2778375690 @default.
• W4379285737 hasConceptScore W4379285737C2780057760 @default.
• W4379285737 hasConceptScore W4379285737C530470458 @default.
• W4379285737 hasConceptScore W4379285737C535046627 @default.
• W4379285737 hasConceptScore W4379285737C71924100 @default.
• W4379285737 hasConceptScore W4379285737C72563966 @default.
• W4379285737 hasFunder F4320332161 @default.
• W4379285737 hasIssue "16_suppl" @default.
• W4379285737 hasLocation W43792857371 @default.
• W4379285737 hasOpenAccess W4379285737 @default.
• W4379285737 hasPrimaryLocation W43792857371 @default.
• W4379285737 hasRelatedWork W144521535 @default.
• W4379285737 hasRelatedWork W2070780645 @default.
• W4379285737 hasRelatedWork W2224319365 @default.
• W4379285737 hasRelatedWork W2294069589 @default.
• W4379285737 hasRelatedWork W2411890706 @default.
• W4379285737 hasRelatedWork W2621592748 @default.
• W4379285737 hasRelatedWork W3181412252 @default.
• W4379285737 hasRelatedWork W4311332848 @default.
• W4379285737 hasRelatedWork W4322760613 @default.
• W4379285737 hasRelatedWork W4322775203 @default.
• W4379285737 hasVolume "41" @default.
• W4379285737 isParatext "false" @default.
• W4379285737 isRetracted "false" @default.
• W4379285737 workType "article" @default.